Cancer Registry (Nevada Central Cancer Registry)(NCCR)

Reporting Options:

• •  Option 1: Secure file upload in text, excel, HL7 or NAACCR format
  •  Option 2:Online abstracting to the NCCR. Web Plus is a web-based application that collects cancer data securely over the public Internet. Web Plus is a web-based abstracting computer program available at no cost, and no software is required to be installed for its use. It is available over a secure Internet connection and access is controlled through NCCR’s assignment of user IDs and passwords. Supporting text is required to be included in the abstracts to verify histology, staging, etc.
  • Option 3: Paper Reporting: Hard copy submission via mail, fax, or file upload of the NCCR cancer incidence reporting form. Supporting documents are required to be included in the abstracts to verify histology, staging, etc.

Each reporting entity must complete the specific “Demographic Form” (attachment below). This form provides the registry with basic information and identifies your option for reporting. Once the completed “Demographic Form” is returned the registry will provide additional reporting depending on the reporting option selected.

The NCCR operates under the Standards set by the National Program of Cancer Registries (NPCR) and the North American Association of Central Cancer Registries (NAACCR).

Information collected includes:

• Patient information (e.g. age, gender, race, address at diagnosis, place of birth, marital status, occupation and industry)
• Anatomic site of the primary tumor
• Histology (cell type) of the cancer
• Stage of disease at diagnosis
• First course of treatment

Nevada Central Cancer Registry
4126 Technology Way, Suite 200
Carson City, NV 89706
Email: dpbhNCCR@health.nv.gov 
Telephone: 775-684-5968
Fax: 775-684-5999

$35 fee per case for using paper form vs. Web Plus; $15 fee for not abstracting to STORE standards

 NAC 457.145  Administrative penalty for violation; appeal; single report authorized for company that operates multiple facilities; imposition of administrative penalty upon company rather than facility. (NRS 457.065, 457.250)

     1.  Before imposing an administrative penalty pursuant to this section, the Division shall give notice in the manner set forth in NAC 439.345 which includes, without limitation, a time determined by the Chief Medical Officer within which the person must correct the violation of NRS 457.250. The Division may, for good cause shown, extend the time within which the person must correct the violation.

     2.  If a person fails to correct an alleged violation of NRS 457.250 for which a notice of violation has been issued pursuant to subsection 1 within the time allowed for correction, the Division may impose an administrative penalty of not more than $5,000 against the person.

     3.  If a person is aggrieved by a decision of the Division relating to the imposition of an administrative penalty pursuant to this section, the aggrieved person may appeal the decision pursuant to the procedures set forth in NAC 439.300 to 439.395, inclusive.

     4.  A company that owns and operates multiple health care facilities may satisfy the requirement set forth in subsection 1 of NRS 457.250 for all such health care facilities in one report without segregating by health care facility, or by provider of health care, the records subject to reporting.

     5.  If a company chooses to make the records subject to reporting available to the Chief Medical Officer or the Chief Medical Officer’s representative for multiple health care facilities owned or operated by the company in the manner described in subsection 4, any administrative penalty imposed by the Board pursuant to this section for the failure of any health care facility owned or operated by the company to comply with subsection 1 of NRS 457.250 will be imposed upon the company rather than the health care facility.

     (Added to NAC by Bd. of Health by R057-16, eff. 5-16-2018)

 NAC 457.150  Fees. (NRS 439.150, 457.065, 457.250, 457.260)  The Chief Medical Officer shall charge and collect from:

     1.  A provider of health care who is required to report information on cases of cancer and other neoplasms pursuant to NRS 457.230 or a health care facility or other facility that provides screening, diagnostic or therapeutic services to patients with respect to cancer and other neoplasms, a fee of $250 for each abstract prepared by the Division from the records of the provider of health care or the health care facility or other facility.

     2.  A medical researcher who obtains data from the registry, a fee of $200 or the actual cost of providing the data, whichever is more.

All diseases with a behavior code of “/2,” in situ disease, or “/3” malignant disease

All solid tumors of brain and central nervous system, including meninges and intracranial
endocrine structures with behavior codes of:

• “/0” benign disease
• “/1” disease of uncertain malignant potential
• “/2” in situ disease
• “/3” malignant disease

2020 Casefinding List: Reportable Neoplasms for Cases Diagnosed in 2020:

C00.- - C43.-,C4A.-, C45.- - C48.-,C49.- -C96.- Malignant neoplasms (excluding category C44 and 49.A), stated or presumed to be primary (of specified site) and certain specified histologies.
C44.00, C44.09 Unspecified/other malignant neoplasm of skin of lip
C44.10-, C44.19- Unspecified/other malignant neoplasm of skin of eyelid
C44.13- Sebaceous cell carcinoma of skin of eyelid, including canthus. Effective 10/1/2018
C44.20-, C44.29- Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44.39- Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44.49- Unspecified/other malignant neoplasm of skin of scalp & neck
C44.50-, C44.59- Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44.69- Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44.79- Unspecified/other malignant neoplasm of skin of lower limb, including hip
C44.80, C44.89 Unspecified/other malignant neoplasm of skin of overlapping sites of skin
C44.90, C44.99 Unspecified/other malignant neoplasm of skin of unspecified sites of skin
C49.A- Gastrointestinal Stromal Tumors Note: GIST is only reportable when it is malignant (/3). GIST, NOS (not stated whether malignant or benign) is a /1 and is not reportable.
D00.- - D09.- In-situ neoplasms Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable
D18.02 Hemangioma of intracranial structures and any site
D32.- Benign neoplasm of meninges (cerebral, spinal and unspecified)
D33.- Benign neoplasm of brain and other parts of central nervous system
D35.2 - D35.4 Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland
D42.-, D43.- Neoplasm of uncertain or unknown behavior of meninges, brain, CNS
D44.3 - D44.5 Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland
D45 Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0),
secondary polycythemia (D75.1)
D46.- Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992)
D47.02 Systemic mastocytosis Note: Effective 10/01/2017
D47.1 Chronic myeloproliferative disease (9963/3, 9975/3) ICD-10-CM Coding instruction note: Excludes the following:
Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_), Chronic myeloid leukemia BCR/ABL-positive
(C92.1_), Myelofibrosis & Secondary myelofibrosis (D75.81), Myelophthisic anemia & Myelophthisis (D61.82)
D47.3 Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia
D47.4 Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis, Myelofibrosis (idiopathic) (with
myeloid metaplasia), Myelosclerosis (megakaryocytic) with myeloid metaplasia), Secondary myelofibrosis in
myeloproliferative disease
D47.9 Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)
D47.Z- Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3,
9970/1, 9971/3, 9931/3)
D49.6, D49.7 Neoplasm of unspecified behavior of brain, endocrine glands and other CNS
R85.614 Cytologic evidence of malignancy on smear of anus
R87.614 Cytologic evidence of malignancy on smear of cervix
R87.624 Cytologic evidence of malignancy on smear of vagina